INTRODUCTION
Assessments of biomarkers in vivo by means of positron emission tomography (PET) for amyloidosis, tau aggregates, and neurodegeneration are becoming indispensable to characterize individual underlying neuropathology in Alzheimer's disease (AD) and other disorders. We and others have previously shown that perfusion-phase amyloid-PET imaging is a potential surrogate biomarker of neurodegeneration, possibly with a capability to substitute for [ 18 F]fluorodeoxyglucose (FDG) PET [1] [2] [3] [4] . With respect to cost and radiation exposure, such "one-stop shops" giving two channels of pathophysiological information in one session are highly desirable. Recently-developed radioligands for imaging of hyperphosphorylated tau [5, 6] assume a role in future classification schemes for AD, which would comprise a three-fold characterization of neurodegeneration, amyloid and tau pathology for the individual patient [7] . A recent study showed that the initial uptake phase for the arylquinoline tau ligand [ 18 F]THK5317 provides information closely related to the pattern of [ 18 F]FDG uptake [8] , presumably due to the general relationship between perfusion and energy metabolism in AD [9] . Thus, we aimed to investigate whether perfusion-phase tau-PET acquisition with the successor arylquinoline ligand [ 18 F]THK5351 also affords this opportunity in clinical routine.
MATERIAL AND METHODS

Patient characteristics and study protocol
A 59-year-old female patient with progressive cognitive impairment over three years (Mini- 
PET acquisition and preparation
[ 18 F]THK5351 PET was performed in a full dynamic 0-90-min setting initiated upon intravenous injection (∼10 s) of 180 MBq of the ligand. The static 40-60-min frame was reconstructed for the clinical read-out of cerebral tau pathology [11] . The perfusion-phase of [ 18 F]THK5351 was reconstructed in a series of 15 frames of 1 min duration each; to account for their lower count statistics, a 6 mm Gaussian filter was applied to each 1-min frames. [ 18 F]FDG PET was performed in a static 30-60-min setting after injection of 125 MBq of the ligand, with reconstruction of a single static frame.
A T1 weighted MRI sequence was used for coregistration of both PET datasets by use of the PNEURO processing pipeline (PMOD technologies, V 3.5, Basel, Switzerland). Data were analyzed in the MNI space after normalization to the global mean uptake.
PET data evaluation
Uptake data of both tracers were compared in three steps: contrasted against an in-house database of agematched cognitively healthy subjects by 3D stereotactic surface projection (3DSSP).
RESULTS
Late-phase [ 18 F]THK5351-PET revealed elevated binding in the bilateral hippocampi, and in the bilateral temporal and parietal cortices. According to recent publications, this tau PET result corresponds to an AD-typical Braak Stage of III-IV.
[ 18 F]FDG PET revealed widespread hypometabolism indicative of synaptic dysfunction in the lateral parietal and temporal cortices, with a minor accentuation of the right hemisphere. Further synaptic dysfunction was observed in the bilateral posterior cingulate gyrus, all of which was indicated an ADtypical glucose metabolism pattern.
DSC were highest in the first minute after tracer injection (DSC: 95%), but decline linearly (R 2 = 0.99) towards the 15-min frame (DSC: 89%) (Fig. 1) .
Visual inspection of axial and sagittal slices indicated a striking agreement between the 0-2 min p.i. acquisition of [ 18 F]THK5351 and standard 30-60-min p.i. [ 18 F]FDG uptake ( Fig. 2A) . Visual comparison of [ 18 F]THK5351 frames ≤5 min p.i. were judged similar, whereas frames >5 min p.i. did not suggest a compelling congruency (Fig. 1 ) to visual read, although DSC values remained high at later frames. 3D-SSP likewise resulted in a highly congruent regional hypometabolism/-perfusion pattern, which was most pronounced in parieto-temporal and posterior cingulate cortices (Fig. 2B) . PET data from cognitively healthy subjects indicated a perfusion-like pattern in the 0-10-min phase after injection [12] . This physiological finding fits to our present observation, although earlier summation images are seemingly better-suited to identify relevant hypoperfusion/-metabolism in neurodegenerative disorders like AD. 
DISCUSSION
Conclusion
A two-phase protocol of dynamic [ 18 F]THK5351 PET may give combined neurodegeneration and tau pathology biomarker information, with savings in cost, time and radiation exposure in clinical routine PET imaging of AD. These pilot results derived from a single patient encourage us to analyze the very early perfusion phase after tracer administration in a large study population.
